Long-term outcome in patients with recurrent malignant glioma treated with perillyl alcohol inhalation

December 2013

Anticancer Research 2013, 33:5625.


This report represents a follow-up on the initial clinical study, performed in Brazil, where perillyl alcohol was administered via inhalation through the nose (intranasal) to 185 patients with brain cancer. It was concluded that after 4 years of exclusive treatment with perillyl alcohol, 19% of patients remained in clinical remission, and long-term inhalational therapy with perillyl alcohol represented a safe and non-invasive strategy for recurrent glioma.

Comments are closed.